Virios Therapeutics IncNASDAQ:VIRINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4252
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4198/ 7
- Ask / Lots0.6500/ 9
- Open / Previous Close0.0000 / 0.4252
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIRI |
|---|---|---|
| 09:32 ET | 1119 | 0.4301 |
| 09:34 ET | 1200 | 0.43499 |
| 09:38 ET | 2278 | 0.4387 |
| 09:39 ET | 3373 | 0.4388 |
| 09:41 ET | 9871 | 0.4495 |
| 09:43 ET | 400 | 0.45 |
| 09:45 ET | 197 | 0.4449 |
| 09:48 ET | 500 | 0.442475 |
| 10:12 ET | 175 | 0.4351 |
| 10:21 ET | 5543 | 0.435 |
| 10:42 ET | 100 | 0.4449 |
| 10:46 ET | 1000 | 0.4449 |
| 10:57 ET | 6332 | 0.4499 |
| 11:00 ET | 8400 | 0.45 |
| 11:04 ET | 1100 | 0.457 |
| 11:08 ET | 323 | 0.457 |
| 11:13 ET | 200 | 0.4579 |
| 11:18 ET | 10975 | 0.4579 |
| 11:24 ET | 1000 | 0.4579 |
| 11:26 ET | 35652 | 0.4747 |
| 11:27 ET | 22218 | 0.4747 |
| 11:31 ET | 26132 | 0.4747 |
| 11:33 ET | 300 | 0.4746 |
| 11:36 ET | 1000 | 0.47 |
| 11:40 ET | 448 | 0.465 |
| 11:42 ET | 165 | 0.4601 |
| 11:47 ET | 250 | 0.4674 |
| 11:51 ET | 300 | 0.4601 |
| 11:58 ET | 3852 | 0.460201 |
| 12:02 ET | 3100 | 0.4747 |
| 12:03 ET | 488 | 0.4602 |
| 12:05 ET | 100 | 0.474599 |
| 12:07 ET | 205 | 0.4746 |
| 12:21 ET | 420 | 0.4746 |
| 12:23 ET | 124 | 0.4746 |
| 12:36 ET | 1000 | 0.4601 |
| 12:54 ET | 8000 | 0.47 |
| 12:59 ET | 212 | 0.47 |
| 01:14 ET | 5100 | 0.4311 |
| 01:15 ET | 131 | 0.4707 |
| 01:26 ET | 212 | 0.4706 |
| 02:33 ET | 26416 | 0.4198 |
| 02:38 ET | 100 | 0.46069 |
| 02:54 ET | 200 | 0.4596 |
| 03:09 ET | 1050 | 0.44 |
| 03:59 ET | 771 | 0.4252 |
Mar 26, 2024
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID, from 9:15AM ET on Tuesday Mar 26, 2024 by Dow Jones
9:15AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Virios Therapeutics Inc | 8.2M | -1.5x | --- |
Cyclerion Therapeutics Inc | 7.5M | -0.5x | --- |
Lixte Biotechnology Holdings Inc | 7.4M | -1.2x | --- |
Protagenic Therapeutics Inc | 7.3M | -1.4x | --- |
Pasithea Therapeutics Corp | 7.2M | -0.5x | --- |
Hepion Pharmaceuticals Inc | 7.2M | -0.1x | --- |
Company Information
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
Contact Information
- Headquarters
- 44 Milton AvenueALPHARETTA, GA, United States 30009
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Gregory Duncan
- Founder, Director
- William Pridgen
- Senior Vice President - Finance
- Angela Walsh
- Senior Vice President of Operations
- Ralph Grosswald
- Chief Medical Officer
- R. Michael Gendreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 19.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.90 |
EPS | $-0.28 |
Book Value | --- |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
